Intuitive Surgical (ISRG) Q3 2026: Revenue Growth Amid Litigation Charges — Mixed Results

Intuitive Surgical (ISRG) reported its third-quarter earnings for 2026, revealing a significant revenue increase but a decline in net income due to substantial litigation charges. The company achieved third-quarter revenue of $3.05 billion, marking an increase of $0.54 billion or +22% compared to $2.51 billion in the same quarter of 2025. However, GAAP net income attributable to Intuitive Surgical, Inc. fell to $523 million, or $1.49 per diluted share, down from $704 million, or $1.95 per diluted share, in the prior year.

Key Financial Metrics

• Revenue:
  • Q3 2026: $3.05 billion
  • Q3 2025: $2.51 billion
  • Increase: $0.54 billion or +22% YoY
• GAAP Net Income:
  • Q3 2026: $523 million or $1.49 per diluted share
  • Q3 2025: $704 million or $1.95 per diluted share
  • Decrease: $181 million or -26% YoY
• Non-GAAP Net Income:
  • Q3 2026: $1.05 billion or $3.00 per diluted share
  • Q3 2025: $867 million or $2.40 per diluted share
  • Increase: $183 million or +21% YoY
• Instruments and Accessories Revenue:
  • Q3 2026: $1.80 billion
  • Q3 2025: $1.52 billion
  • Increase: $0.28 billion or +18% YoY
• Systems Revenue:
  • Q3 2026: $769 million
  • Q3 2025: $590 million
  • Increase: $0.18 billion or +30% YoY
• Share Repurchases:
  • 7.8 million shares repurchased for $2.94 billion.

Analyst View

This quarter presents a mixed bag for shareholders. While the revenue growth of 22% is impressive and reflects strong demand for Intuitive's surgical systems, the decline in GAAP net income due to a $450 million litigation charge related to antitrust class action settlements raises concerns. The company’s ability to generate non-GAAP net income growth of 21% indicates operational strength, but the litigation costs overshadow this positive performance.

The substantial share repurchase program, totaling $2.94 billion, signals management's confidence in the company's long-term value, but the ongoing litigation could pose risks to future profitability and investor sentiment.

Dividend and Guidance

Intuitive Surgical did not announce any changes to its dividend policy in this earnings release. The company maintains its guidance for worldwide da Vinci procedure growth of approximately 14% to 15% for the full year of 2026, with expectations to be closer to the midpoint of this range. Non-GAAP gross profit margin is projected to be between 68.7% to 69.3% of revenue, which includes an estimated impact from tariffs.

Forward Catalysts

Investors should closely monitor the outcome of the antitrust litigation and its potential impact on future earnings. Additionally, the company's ability to sustain its growth trajectory in procedures and system placements will be critical. The upcoming quarters will also reveal how effectively Intuitive can manage its operating expenses and navigate the challenges posed by tariffs and litigation costs. The market will be keenly watching for updates on the settlement approval and any further developments in the competitive landscape of robotic-assisted surgery.

Note: All amounts are in millions.

Disclaimer

The content on MarketsFN.com is provided for educational and informational purposes only. It does not constitute financial advice, investment recommendations, or trading guidance. All investments carry risk and past performance does not guarantee future results. You are solely responsible for your investment decisions and should conduct independent research and consult a qualified financial advisor before acting. MarketsFN.com and its authors are not liable for any losses or damages arising from the use of this information.